61 studies on Sermorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,049 published Sermorelin COA source records from third-party laboratories, covering 399 publicly attributable vendor identities. Across 918 records with positive numeric purity, the arithmetic mean is 99.2%. 2 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 4 positive purity results are below 90%; 34 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-14. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $6.50 | $6.50–$6.50 | $3.25 | 1 source · 1 offer |
| 5 mg | $9.83 | $9.00–$10.50 | $1.97 | 3 sources · 3 offers |
| 10 mg | $15.50 | $14.50–$16.50 | $1.55 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-14. Aggregate calculated: 2026-10-18T05:13:55.056470+00:00. Calculation time is not a laboratory observation date.
Within that total, 249 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 26 | 99.24% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 13 | 99.29% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 14 | 99.03% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119432 (99.2%) · #120426 (99.69%) · #119967 (99.18%) · #119623 (99.61%) · #118949 (99.39%) · #118371 (99.64%)
This research provides crucial insights, suggesting that the anti-cancer effects of GHRH antagonists may be mediated, at least in part, through the induction of autophagy. Autophagy can lead to programmed cell death o…
This report highlights that the illicit drug market in Europe extends beyond commonly recognized categories like ED drugs. For users of peptides and other biopharmaceuticals, this is a stark reminder of the risks asso…
**Clinicians and peptide users combining GHS with GHRH analogs** (e.g., sermorelin or CJC-1295) should note the synergistic GH release depends entirely on hypothalamo-pituitary integrity — individuals with hypothalami…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
For clinicians and individuals managing hypogonadism, this review positions GHS like ipamorelin as a potential next-frontier adjunctive therapy to testosterone, specifically for targeting body composition issues like …
This new comprehensive testing protocol represents a significant upgrade for anti-doping agencies. By enabling the simultaneous screening of numerous peptides like CJC-1295, insulins, and growth factors in a single ru…
This highly sensitive detection method provides sports anti-doping agencies with a powerful new tool for identifying the use of prohibited GHRHs like CJC-1295. For athletes and individuals using these peptides, this s…
This research provides anti-doping laboratories with a validated, highly sensitive protocol for detecting **CJC-1295** and similar banned peptides. For athletes using these substances, this significantly increases the…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown me…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing vi…
Free, no account — handy when you're working with Sermorelin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account